Riyadh: Minister of Industry and Mineral Resources and Chairman of the Vaccines and Biopharmaceutical Industry Committee Bandar Alkhorayef welcomed Lifera's signing of seven strategic partnerships with leading global and local companies to localize vaccine and biopharmaceutical production in Saudi Arabia. Lifera is one of the Public Investment Fund's (PIF) companies.
According to Saudi Press Agency, Alkhorayef said the agreements are a pivotal step to strengthen the national pharmaceutical ecosystem and advance Vision 2030 objectives through knowledge and technology transfer, human capital development, and expanded manufacturing capacity, boosting local content and enhancing self-sufficiency in vaccine and biopharmaceutical output.
Lifera's agreements include: a memorandum of understanding under a contract development and manufacturing organization (CDMO) model with Jamjoom Pharmaceuticals Factory Company (Jamjoom Pharma) to build local manufacturing capabilities and localize value chains; four memoranda of understanding to localize vaccines with MSD, Pfizer, Sanofi and GSK. The agreements also include a memorandum of understanding on cell and gene therapies with King Faisal Specialist Hospital and Research Centre to develop and manufacture advanced therapies domestically; and a memorandum of understanding on genomic screening and sequencing between Lean Business Services and CENTOGENE to localize genomic data and analytics.